esc semaglutide FDA Clears For Cardiac Risk Reduction in Diabetic Patients ESC 2025: Novo Nordisk's Wegovy

Because this drug showed no disproportionality signal for ischemic optic neuropathy, the study suggests that the risk of NAION may be GLP-1-specific rather than purely metabolic

Patient characteristics at baseline, treatment initiation, and after 1 year of follow-up are presented in Table 1

Several observational studies show adults with ADHD have similar or slightly better weight loss responses on GLP-1 medications than the general population, especially when combined with appropriate stimulant therapy

But there are serious risks to splitting semaglutide doses

metformin) before approving a more expensive drug like tirzepatide